A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

The researchers found that individual SGLT-2 inhibitors showed similar cardiovascular effectiveness at clinically effective ...

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

Learn how diabetes medications could revolutionize stroke prevention and enhance heart and brain health with breakthrough ...

New research shows diabetes medication SGLT-2 inhibitors lower dementia risk by up to 35%, offering hope for millions ...

Contemporary guidelines recommend diuretic therapy and treatment with sodium–glucose cotransporter 2 (SGLT2) inhibitors for acute heart failure to reduce congestion and the continuation of SGLT2 ...

A new and increasingly widely used diabetes medication may have additional health benefits for older adults, according to new ...

A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...